Abstract

Chemotherapy induced peripheral neuropathy (CIPN) is a severe neurodegenerative disorder caused by chemotherapy drugs. Berberine is a natural monomer compound of Coptis chinensis, which has anti-tumor effect and can improve neuropathy through anti-inflammatory mechanisms. Transient receptor potential vanilloid (TRPV1) can sense noxious thermal and chemical stimuli, which is an important target for the study of pathological pain. In both vivo and in vitro CIPN models, we found that berberine alleviated peripheral neuropathy associated with dorsal root ganglia inflammation induced by cisplatin. We confirmed that berberine mediated the neuroinflammatory reaction induced by cisplatin by inhibiting the overexpression of TRPV1 and NF-κB and activating the JNK/p38 MAPK pathways in early injury, which inhibited the expression of p-JNK and mediated the expression of p38 MAPK/ERK in late injury in vivo. Moreover, genetic deletion of TRPV1 significantly reduced the protective effects of berberine on mechanical and heat hyperalgesia in mice. In TRPV1 knockout mice, the expression of NF-κB increased in late stage, and berberine inhibited the overexpression of NF-κB and p-ERK in late injury. Our results support berberine can reverse neuropathic inflammatory pain response induced by cisplatin, TRPV1 may be involved in this process.

Highlights

  • IntroductionThe platinum analogue cisplatin (cis-di-amino-di-chloro-platinum, CDDP) was the first platinumbased cytotoxic agent (Quasthoff and Hartung, 2002)

  • The platinum analogue cisplatin was the first platinumbased cytotoxic agent (Quasthoff and Hartung, 2002)

  • This study showed that a single dose of CDDP caused thermal hyperalgesia for 2 h in mice, and the thermal hyperalgesia gradually disappeared in 1–2 h

Read more

Summary

Introduction

The platinum analogue cisplatin (cis-di-amino-di-chloro-platinum, CDDP) was the first platinumbased cytotoxic agent (Quasthoff and Hartung, 2002). Platinum-based chemotherapeutics are notably toxic to neurons. Platinum leads to the dysfunction of neuronal membrane excitability and disruption of neurotransmission, induction of inflammation via release of proinflammatory chemokines, and alteration of voltage-gated ion channels expression (Ibrahim and Ehrlich, 2020). Platinum induces apoptosis in sensory neurons (Fukuda et al, 2017), resulting in chronic dose-dependent pain and sensory changes. There is no specific clinic drug for treating CIPN. The main clinical treatment is analgesia, supplemented with other sedative drugs. Nonsteroidal anti-inflammatory drugs can temporarily control symptoms for some patients, but the treatment effect in most patients is not satisfactory. A variety of Berberine Attenuated Inflammatory in CIPN pharmacologic agents have been evaluated for the treatment of CIPN, only duloxetine (DLX) has been recommended to treat CIPN by American Society of Clinical Oncology

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call